|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta GP and Massague J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyer KD and Jaffrey SR: The dynamic
epitranscriptome: N6-methyladenosine and gene expression control.
Nat Rev Mol Cell Biol. 15:313–326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin S, Choe J, Du P, Triboulet R and
Gregory RI: The m(6)A Methyltransferase METTL3 promotes translation
in human cancer cells. Mol Cell. 62:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang
Z, Liu Y, Zhang X, Zhang W and Ye L: HBXIP-elevated
methyltransferase METTL3 promotes the progression of breast cancer
via inhibiting tumor suppressor let-7g. Cancer Lett. 415:11–19.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang S, Guan H, Lin X, Li N, Geng F and
Li J: METTL3 serves an oncogenic role in human ovarian cancer cells
partially via the AKT signaling pathway. Oncol Lett. 19:3197–3204.
2020.PubMed/NCBI
|
|
9
|
Okugawa Y, Toiyama Y, Hur K, Toden S,
Saigusa S, Tanaka K, Inoue Y, Mohri Y, Kusunoki M, Boland CR and
Goel A: Metastasis-associated long non-coding RNA drives gastric
cancer development and promotes peritoneal metastasis.
Carcinogenesis. 35:2731–2739. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okugawa Y, Tanaka K, Inoue Y, Kawamura M,
Kawamoto A, Hiro J, Saigusa S, Toiyama Y, Ohi M, Uchida K, et al:
Brain-derived neurotrophic factor/tropomyosin-related kinase B
pathway in gastric cancer. Br J Cancer. 108:121–130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okugawa Y, Inoue Y, Tanaka K, Kawamura M,
Saigusa S, Toiyama Y, Ohi M, Uchida K, Mohri Y and Kusunoki M: Smad
interacting protein 1 (SIP1) is associated with peritoneal
carcinomatosis in intestinal type gastric cancer. Clin Exp
Metastasis. 30:417–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okugawa Y, Toiyama Y, Tanaka K, Matsusita
K, Fujikawa H, Saigusa S, Ohi M, Inoue Y, Mohri Y, Uchida K and
Kusunoki M: Clinical significance of Zinc finger E-box Binding
homeobox 1 (ZEB1) in human gastric cancer. J Surg Oncol.
106:280–285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ichikawa T, Okugawa Y, Toiyama Y, Tanaka
K, Yin C, Kitajima T, Kondo S, Shimura T, Ohi M, Araki T and
Kusunoki M: Clinical significance and biological role of L1 cell
adhesion molecule in gastric cancer. Br J Cancer. 121:1058–1068.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okugawa Y, Toiyama Y, Shigeyasu K,
Yamamoto A, Shigemori T, Yin C, Ichikawa T, Yasuda H, Fujikawa H,
Yoshiyama S, et al: Enhanced AZIN1 RNA editing and overexpression
of its regulatory enzyme ADAR1 are important prognostic biomarkers
in gastric cancer. J Transl Med. 16:3662018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okugawa Y, Mohri Y, Tanaka K, Kawamura M,
Saigusa S, Toiyama Y, Ohi M, Inoue Y, Miki C and Kusunoki M:
Metastasis-associated protein is a predictive biomarker for
metastasis and recurrence in gastric cancer. Oncol Rep.
36:1893–1900. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toiyama Y, Yasuda H, Saigusa S, Tanaka K,
Inoue Y, Goel A and Kusunoki M: Increased expression of Slug and
Vimentin as novel predictive biomarkers for lymph node metastasis
and poor prognosis in colorectal cancer. Carcinogenesis.
34:2548–2557. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Austin PC: An introduction to propensity
score methods for reducing the effects of confounding in
observational studies. Multivariate Behav Res. 46:399–424. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frisch SM and Francis H: Disruption of
epithelial cell-matrix interactions induces apoptosis. J Cell Biol.
124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eccles SA and Welch DR: Metastasis: Recent
discoveries and novel treatment strategies. Lancet. 369:1742–1757.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shitara K, Doi T, Dvorkin M, Mansoor W,
Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova
V, et al: Trifluridine/tipiracil versus placebo in patients with
heavily pretreated metastatic gastric cancer (TAGS): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
19:1437–1448. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshida K, Kodera Y, Kochi M, Ichikawa W,
Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, et
al: Addition of docetaxel to oral fluoropyrimidine improves
efficacy in patients with stage III Gastric cancer: Interim
Analysis of JACCRO GC-07, a randomized controlled trial. J Clin
Oncol. 37:1296–1304. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujitani K, Yang HK, Mizusawa J, Kim YW,
Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, et
al: Gastrectomy plus chemotherapy versus chemotherapy alone for
advanced gastric cancer with a single non-curable factor (REGATTA):
A phase 3, randomised controlled trial. Lancet Oncol. 17:309–318.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen XY, Zhang J and Zhu JS: The role of
m(6)A RNA methylation in human cancer. Mol Cancer. 18:1032019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lan Q, Liu PY, Haase J, Bell JL,
Hüttelmaier S and Liu T: The critical Role of RNA m(6)A Methylation
in cancer. Cancer Res. 79:1285–1292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin Y, Wei X, Jian Z and Zhang X: METTL3
expression is associated with glycolysis metabolism and sensitivity
to glycolytic stress in hepatocellular carcinoma. Cancer Med.
9:2859–2867. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hua W, Zhao Y, Jin X, Yu D, He J, Xie D
and Duan P: METTL3 promotes ovarian carcinoma growth and invasion
through the regulation of AXL translation and epithelial to
mesenchymal transition. Gynecol Oncol. 151:356–365. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okugawa Y, Grady WM and Goel A: Epigenetic
alterations in colorectal cancer: Emerging biomarkers.
Gastroenterology. 149:1204–1225.e12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adams JM and Cory S: Modified nucleosides
and bizarre 5′-Termini in mouse myeloma mRNA. Nature. 255:28–33.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Desrosiers R, Friderici K and Rottman F:
Identification of methylated nucleosides in messenger RNA from
Novikoff hepatoma cells. Proc Natl Acad Sci USA. 71:3971–3975.
1974. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao BS, Roundtree IA and He C:
Post-transcriptional gene regulation by mRNA modifications. Nat Rev
Mol Cell Biol. 18:31–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wei W, Ji X, Guo X and Ji S: Regulatory
role of N6-methyladenosine (m6A) methylation
in rna processing and human diseases. J Cell Biochem.
118:2534–2543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang
L, Jia G, Yu M, Lu Z, Deng X, et al: A METTL3-METTL14 complex
mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem
Biol. 10:93–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H,
Wu M, Liang Y, Zhu F, Zhang Y, Zhang X, et al: The m6A
methyltransferase METTL3 promotes bladder cancer progression via
AFF4/NF-κB/MYC signaling network. Oncogene. 38:3667–3680. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen M, Wei L, Law CT, Tsang FH, Shen J,
Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al: RNA
N6-methyladenosine methyltransferase-like 3 promotes liver cancer
progression through YTHDF2-dependent posttranscriptional silencing
of SOCS2. Hepatology. 67:2254–2270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Barbieri I, Tzelepis K, Pandolfini L, Shi
J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister
AJ, Han N, et al: Promoter-bound METTL3 maintains myeloid leukaemia
by m6A-dependent translation control. Nature.
552:126–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
